

INFORMATION DISCLOSURE STATEMENT

Applicant : Gu et al.
App. No : 10/729,027
Filed : December 5, 2003
For : LIPOOLIGOSACCHARIDE-BASED
VACCINE FOR PREVENTION OF
MORAXELLA (BRANHAMELLA)
CATARRHALIS INFECTIONS IN
HUMANS
Examiner : Ford, Vanessa L.
Art Unit : 1645

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing six references to be considered by the Examiner. Also enclosed are six foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p).

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 11/10/05

By: 
Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 45,311
(805) 547-5580

11/16/2005 MBERHE 00000017 10729027

01 FC:1806 180.00 OP

IDS 2052725:vb 110805

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary) SHEET 1 OF 1	Application No.	10/729,027
	Filing Date	December 5, 2003
	First Named Inventor	Gu et al.
	Art Unit	1645
	Examiner	Ford, Vanessa L.
Attorney Docket No.		NIH142.1CDV1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1.	GU, X-X et al., May 1998, "Synthesis and Characterization of Lipooligosaccharide-Based Conjugates as Vaccine Candidates for <i>Moraxella (Branhamella) catarrhalis</i> ," Infect Immun 66: 1891.	
	2.	HU, W-G et al., Sept 2000, "Enhancement of Clearance of Bacteria from Murine Lungs by Immunization with Detoxified Lipooligosaccharide from <i>Moraxella catarrhalis</i> Conjugated to Proteins," Infect Immun 68: 4980.	
	3.	HU, W-G et al., March 2001, "Functional Characteristics of a Protective Monoclonal Antibody against Serotype A and C Lipooligosaccharides from <i>Moraxella catarrhalis</i> ," Infect Immun 69: 1358.	
	4.	JIAO, X et al., Nov 2002, "Specific Immune Responses and Enhancement of Murine Pulmonary Clearance of <i>Moraxella catarrhalis</i> by Intranasal Immunization with a Detoxified Lipooligosaccharide Conjugate Vaccine," Infect Immun 70: 5982.	
	5.	YU, S and GU, X-X, May 2005, "Synthesis and Characterization of Lipooligosaccharide-Based Conjugate Vaccines for Serotype B <i>Moraxella catarrhalis</i> ," Infect Immun 73: 2790.	
	6.	YU, S and GU, X-X, June 5-9, 2005, "Biological Characteristics of Lipooligosaccharide-Based Conjugate Vaccines for Serotype C <i>Moraxella catarrhalis</i> ," Abstract of the 105th general meeting of the ASM, Atlanta, Georgia, p. 252.	

2053279:vb
110805

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.